Clinical Trial Update: Duodenal ReCET as an Early Treatment for Type 2 DM [NA]

View source ↗

Summary

A clinical trial update describes evaluating a duodenal ReCET procedure as an early treatment for type 2 diabetes mellitus, with the study not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Fatty Liver Disease
• Type 2 Diabetes Mellitus

Drugs mentioned

• Duodenal ReCET

Snippet

Sponsor: Chinese University of Hong Kong | Conditions: Diabete Mellitus, T2 Diabetes and Fatty Liver Disease (Non-alcoholic Origin) | NA | Status: NOT_YET_RECRUITING